BioWorld

Nov. 25, 2008

Alpharma Rethinks King's Bid, Agrees to be Acquired for $1.6B

Two months after urging shareholders to reject a $37-per-share offer from King Pharmaceuticals Inc., Alpharma Inc. changed its mind and agreed to the merger, which values the specialty pharma firm at about $1.6 billion. (BioWorld Today) Read More

J&J Seeks to Acquire Omrix in $438M Cash Tender Offer

Host Cell Components Promising Broad-Spectrum Antiviral Targets

NewCo News: Compellis Does Obesity Drug Development by the Nose

Another Depomed Deal: $68M Delivery License with Covidien

Naproxcinod Meets Endpoints in Third Phase III Arthritis Trial

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...